First-line fulvestrant plus anastrozole for hormone-receptor-positive metastatic breast cancer in postmenopausal women: a cost-effectiveness analysis

被引：0
|
作者：
Weiting Liao
Jiaxing Huang
Qiuji Wu
Feng Wen
Nan Zhang
Kexun Zhou
Liangliang Bai
Qiu Li
机构：
[1] Sichuan University,Department of Medical Oncology, Cancer Center, West China Hospital
[2] Sichuan University,West China Biomedical Big Data Center
来源：
Breast Cancer | 2020年 / 27卷
关键词：
Cost-effectiveness analysis; Breast cancer; Hormone-receptor-positive; Fulvestrant; Anastrozole; Dual endocrine therapy;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：399 / 404
页数：5
相关论文
共 50 条
  • [1] First-line fulvestrant plus anastrozole for hormone-receptor-positive metastatic breast cancer in postmenopausal women: a cost-effectiveness analysis
    Liao, Weiting
    Huang, Jiaxing
    Wu, Qiuji
    Wen, Feng
    Zhang, Nan
    Zhou, Kexun
    Bai, Liangliang
    Li, Qiu
    BREAST CANCER, 2020, 27 (03) : 399 - 404
  • [2] Half-dose fulvestrant plus anastrozole as a first-line treatment for hormone receptor-positive metastatic breast cancer: a cost-effectiveness analysis
    Huang, Xiaoting
    Weng, Xiuhua
    Lin, Shen
    Liu, Yiwei
    Luo, Shaohong
    Wang, Hang
    Ming, Wai-kit
    Huang, Pinfang
    BMJ OPEN, 2020, 10 (08):
  • [3] Cost-effectiveness analysis of fulvestrant versus anastrozole as first-line treatment for hormone receptor-positive advanced breast cancer
    Ding, H.
    Fang, L.
    Xin, W.
    Tong, Y.
    Zhou, Q.
    Huang, P.
    EUROPEAN JOURNAL OF CANCER CARE, 2017, 26 (06)
  • [4] First-line Treatment with Ribociclib plus Endocrine Therapy for Premenopausal Women with Hormone-receptor-positive Advanced Breast Cancer: A Cost-effectiveness Analysis
    Huang, Xiaoting
    Lin, Shen
    Rao, Xin
    Zeng, Dayong
    Wang, Hang
    Weng, Xiuhua
    Huang, Pinfang
    CLINICAL BREAST CANCER, 2021, 21 (04) : E479 - E488
  • [5] Cost-effectiveness of anastrozole versus tamoxifen as first-line therapy for postmenopausal hormone-receptor positive advanced breast cancer.
    Sobocki, P.
    Borgstrom, F.
    Kasteng, F.
    Paulsson, T.
    Lidgren, M.
    Henriksson, R.
    Lundkvist, J.
    BREAST CANCER RESEARCH AND TREATMENT, 2006, 100 : S230 - S230
  • [6] Fulvestrant plus anastrozole as neoadjuvant therapy in postmenopausal women with hormone receptor positive early breast cancer
    Khan, Q. J.
    Barr, J. A.
    Britt, A. S.
    Kimler, B. F.
    Connor, C. S.
    McGinness, M.
    Mammen, J. M. V.
    Wagner, J. L.
    Amin, A.
    Springer, M.
    Baccaray, S.
    Fabian, C. J.
    Sing, A. P.
    Sharma, P.
    CANCER RESEARCH, 2016, 76
  • [7] Cost-effectiveness of anastrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer
    Simons, WR
    Jones, D
    Buzdar, A
    CLINICAL THERAPEUTICS, 2003, 25 (11) : 2972 - 2987
  • [8] Cost-effectiveness of everolimus plus exemestane in postmenopausal hormone receptor positive metastatic breast cancer
    Zeichner, Simon B.
    Avancha, Kiran Kumar Venkata Raja
    Lopes, Gilberto
    Gluck, Stefan
    Montero, Alberto J.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [9] RE: "Cost-effectiveness analysis of fulvestrant versus anastrozole as first-line treatment for hormone receptor-positive advanced breast cancer," by Ding H., etal.
    Telford, Claire
    EUROPEAN JOURNAL OF CANCER CARE, 2018, 27 (02)
  • [10] A randomized trial of combination anastrozole plus gefitinib and of combination fulvestrant plus gefitinib in the treatment of postmenopausal women with hormone receptor positive metastatic breast cancer
    Robert W. Carlson
    Anne O’Neill
    Tatiana Vidaurre
    Henry L. Gomez
    Sunil S. Badve
    George W. Sledge
    Breast Cancer Research and Treatment, 2012, 133 : 1049 - 1056
12345